Fundamentals - AlphaKey Financial

Stock Fundamentals

Company Information

▼

Company Name

Biohaven Pharmaceutical Holding Co Ltd

Sector

Healthcare

Industry

Biotechnology

Exchange

NYSE

ISIN: VGG111961055

CIK: 0001689813

Currency: USD

Full Time Employees: 274

Phone: 203 404 0410

Website: https://www.biohaven.com

Fiscal Year End: December

IPO Date: Sep 23, 2022

Description:

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Address:

215 Church Street, New Haven, CT, United States, 06510

Directors & Officers

▼

Name	Title	Year Born
Dr. Vladimir Coric M.D.	Chairman & CEO	1971
Dr. Bruce D. Car DACVP, Ph.D.	Chief Scientific Officer	1962
Ms. Kimberly Gentile	Senior Vice President of Clinical Operations	1966
Ms. Deb Young	Senior Director of Regulatory Affairs & Operations	NA
Ms. Jennifer Porcelli	Vice President of Investor Relations	NA
Mr. Warren Volles J.D.	General Counsel & Chief Legal Officer	NA
Mr. Clifford Bechtold M.S.	President & GM of Biohaven Ireland Chief Compliance Officer	NA
Mr. John Tilton	Chief Commercial Officer of Rare Diseases	1968
Mr. Chris Barrett	Senior Vice President of Commercial Strategy & Common Disease	NA
Ms. Marianne Frost M.A.	Senior Vice President of Regulatory Affairs	NA

Institutional Holders

▼

Holder Name	Shares	Date Reported	% Out	Value	% Change
Aberdeen Group PLC	693.45K	Dec 31, 2025	0.46%	$0.01	0.00%

Shares Statistics

▼

Shares Outstanding: 150.42M

Shares Float: 123.89M

% Insiders: 839.50%

% Institutions: 7,929.80%

Short % Float: 15.17%

🏆 Top 10 Institutional Holders

▼

Rank	Holder Name	Shares Held	% of Shares	Change	Date Reported
1	Aberdeen Group PLC	693.45K	0.46%	▲ 0.00%	Dec 31, 2025

Valuation Metrics

▼

Enterprise Value: $1.41B

Trailing P/E: 0.00

Forward P/E: 0.00

Financial Highlights

▼

Market Cap: $1.44B

EBITDA: $-698.45M

Book Value: $0.39

Earnings/Share: $-6.86

Profit Margin: 0.00%

Operating Margin: 0.00%

ROA (TTM): -83.02%

ROE (TTM): -310.75%

Revenue (TTM): $0.00

Revenue/Share (TTM): $0.00

Earnings Growth (YOY): 0.00%

Revenue Growth (YOY): 0.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Download Financials (Excel)

Financial Charts

▼

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

Earnings History

▼

Date	EPS Actual	EPS Estimate	Difference	Surprise %
Mar 31, 2026	0.00	-1.04	N/A	10,000.00%
Dec 31, 2025	-0.90	-1.18	N/A	2,372.88%
Sep 30, 2025	-1.64	-1.88	N/A	1,276.60%
Jun 30, 2025	-1.94	-1.94	N/A	0.00%
Mar 31, 2025	-2.17	-1.70	N/A	-2,764.71%
Dec 31, 2024	-1.71	-1.60	N/A	-687.50%
Sep 30, 2024	-1.74	-1.70	N/A	-235.29%
Jun 30, 2024	-3.50	-1.78	N/A	-9,662.92%
Mar 31, 2024	-2.20	-1.57	N/A	-4,012.74%
Dec 31, 2023	-1.81	-1.41	N/A	-2,836.88%
Sep 30, 2023	-1.50	-1.34	N/A	-1,194.03%
Jun 30, 2023	-1.32	-1.21	N/A	-909.09%
Mar 31, 2023	-1.03	-1.41	N/A	2,695.04%
Dec 31, 2022	-3.32	-1.22	N/A	-17,213.11%
Sep 30, 2022	-1.75	-2.34	N/A	2,521.37%
Jun 30, 2022	-6.21	-2.58	N/A	-14,069.77%
Mar 31, 2022	-2.97	-2.53	N/A	-1,739.13%
Dec 31, 2021	-3.01	-2.04	N/A	-4,754.90%
Sep 30, 2021	-2.63	-2.40	N/A	-958.33%
Jun 30, 2021	-3.23	-2.72	N/A	-1,875.00%
Mar 31, 2021	-4.21	-2.82	N/A	-4,929.08%
Dec 31, 2020	-3.62	-2.97	N/A	-2,188.55%
Sep 30, 2020	-3.27	-2.89	N/A	-1,314.88%
Jun 30, 2020	-3.08	-2.61	N/A	-1,800.77%
Mar 31, 2020	-3.07	-2.34	N/A	-3,119.66%
Dec 31, 2019	-2.85	-1.87	N/A	-5,240.64%
Sep 30, 2019	-2.04	-1.57	N/A	-2,993.63%
Jun 30, 2019	-4.67	-1.92	N/A	-14,322.92%
Mar 31, 2019	-1.41	-1.48	N/A	472.97%
Dec 31, 2018	-1.34	-1.21	N/A	-1,074.38%
Sep 30, 2018	-1.53	-1.07	N/A	-4,299.07%
Jun 30, 2018	-1.01	-1.18	N/A	1,440.68%
Mar 31, 2018	-2.32	-1.14	N/A	-10,350.88%
Dec 31, 2017	-0.75	-1.20	N/A	3,750.00%
Sep 30, 2017	-1.19	-1.10	N/A	-818.18%
Jun 30, 2017	-1.78	-0.61	N/A	-19,180.33%
Mar 31, 2017	-1.74	-0.79	N/A	-12,025.32%
Dec 31, 2016	0.00	0.00	N/A	N/A
Dec 31, 1990	-4.67	0.00	N/A	N/A

Balance Sheet (Yearly)

▼

Date	Cash	Total Debt	Total Assets	Total Liabilities	Total Equity
2025-12-31	$229.96M	$N/A	$451.45M	$399.38M	$52.07M
2024-12-31	$99.13M	$N/A	$615.11M	$191.67M	$423.44M
2023-12-31	$248.40M	$N/A	$513.21M	$85.24M	$427.98M
2022-12-31	$204.88M	$N/A	$661.78M	$123.01M	$538.77M
2021-12-31	$76.06M	$N/A	$142.06M	$47.37M	$34.69M
2020-12-31	$82.51M	$N/A	$111.50M	$34.72M	$16.78M
2019-12-31	$316.73M	$N/A	$344.26M	$351.69M	$-7.42M
2018-12-31	$264.25M	$N/A	$290.01M	$139.09M	$150.92M
2017-12-31	$131.47M	$N/A	$146.89M	$14.92M	$131.97M

Financial Ratios

▼

Date	Current Ratio	Debt/Equity	Debt/Assets	Interest Coverage	Debt/EBITDA
2025-12-31	3.18x	4.59x	0.88x	N/A	-0.33x
2024-12-31	3.49x	0.01x	0.31x	N/A	0.00x
2023-12-31	7.98x	0.01x	0.17x	N/A	-0.01x
2022-12-31	6.52x	0.01x	0.19x	-409.76x	-0.01x
2021-12-31	2.26x	18.08x	0.33x	-5.27x	-2.88x
2020-12-31	3.00x	0.04x	0.31x	N/A	-0.01x
2019-12-31	4.96x	0.00x	1.02x	-37.69x	0.00x
2018-12-31	13.94x	0.00x	0.48x	N/A	N/A
2017-12-31	14.49x	0.00x	0.10x	N/A	0.00x

Insider Trading

Date	Insider Name	Title	Transaction Type	Shares	Price	Value
Nov 17, 2025	George C Clark	N/A	Purchase	17.00K	$8.52	$144.84K
Nov 13, 2025	Gregory Bailey	N/A	Purchase	400.00K	$7.50	$3.00M
Nov 13, 2025	John W Childs	N/A	Purchase	3.33M	$7.50	$25.00M
Nov 13, 2025	Vlad Coric	N/A	Purchase	666.67K	$7.50	$5.00M

📦 Raw API Data (JSON Explorer)

▼

Comprehensive raw data returned from the EOD Fundamentals API. Expand sections below to drill down.

Stock Fundamentals

Company Information

Directors & Officers

Institutional Holders

Shares Statistics

🏆 Top 10 Institutional Holders

Valuation Metrics

Financial Highlights

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Earnings History

Balance Sheet (Yearly)

Financial Ratios

Insider Trading

📦 Raw API Data (JSON Explorer)

Watchlist

Assistant